Q4 2026 Elite Pharmaceuticals Inc Earnings Call Transcript
Key Points
- Elite Pharmaceuticals Inc (ELTP) reported a significant revenue increase of 77% year-over-year, reaching $149 million.
- Operating income saw a substantial rise, increasing by 151% to $49 million, indicating strong profitability.
- The company has successfully launched several new generic products, including Vyvanse, Tylenol with Codeine, and Percocet, contributing to revenue growth.
- Elite Pharmaceuticals Inc (ELTP) has a strong balance sheet with cash increasing by 163% to $29.8 million and long-term debt decreasing by 20%.
- The company is considering uplisting to NASDAQ, which could enhance its visibility and attract more investors.
- Despite strong financial performance, the stock price has not reacted positively, which is a concern for management.
- The company faces challenges with patent issues and FDA approval timelines, particularly with its Oxycontin ANDA.
- There is uncertainty regarding the potential dilution from outstanding warrants, which could impact shareholder value.
- Elite Pharmaceuticals Inc (ELTP) has not yet secured a first-to-file position for its anticoagulant ANDA, which could affect its market entry strategy.
- The company is still operating on a single production shift, indicating potential capacity constraints if demand increases significantly.
Good morning, ladies and gentlemen, and welcome to the Elite Pharmaceuticals year-end of Fiscal Year 2026 conference call.
At this time, all lines are placed on a listen-only mode.
Before management begins speaking, the conference has the following statement.
Elite would like to remind listeners that remarks made during this call may contain forward-looking statements that involve risks and uncertainties that are subject to change at any time. Including, but not limited to, statements about Elite's expectations regarding forward operating results.
Forward-looking statements are made pursuant to the safe harbor provisions of the federal securities laws and represent management's current expectations.
Actual results may differ materially.
Elite disclaims any obligation to update or revise its forward-looking statements except as required by law.
More complete information regarding forward-looking statements, risks and uncertainties. Can be found in the Reports Elite files with the SEC which are available on Elite's website at elitepharma
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
